Sunesis Pharmaceuticals (SNSS) Stock Price, News & Analysis

Company Overview

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $2.38 to $5.32
• 52-Week Range: N/A
• Volume: 1.20 million shs
• Average Volume: 4.33 million shs
• Market Capitalization: $96.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SNSS Stock Analysis - Frequently Asked Questions

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) issued its quarterly earnings results on Sunday, November, 15th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.01.

When did Sunesis Pharmaceuticals' stock split?

Sunesis Pharmaceuticals's stock reverse split before market open on Thursday, September 3rd 2020. The 1-10 reverse split was announced on Wednesday, September 2nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Sunesis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sunesis Pharmaceuticals investors own include SELLAS Life Sciences Group (SLS), Novavax (NVAX), NVIDIA (NVDA), QUALCOMM (QCOM), OPKO Health (OPK), TherapeuticsMD (TXMD) and VBI Vaccines (VBIV).

Company Calendar

• Last Earnings: 11/15/2020
• Today: 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SNSS
• CUSIP: 86732860
• CIK: 1061027
• Web: www.sunesis.com
• Phone: 650-266-3500
• Fax: N/A
• Employees: 24
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-23,330,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -179.05%
• Return on Assets: -72.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.74
• Quick Ratio: 7.74

Sales & Book Value

• Annual Sales: $2.07 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.42 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,093,000
• Free Float: N/A
• Market Cap: $96.26 million
• Optionable: Optionable
• Beta: 2.27